Skip to main content
SpringerLink
Log in

New Trends in the Treatment of Osteoporosis

  • Chapter
Recent Advances in Geriatrics

Abstract

Osteoporosis is “a systemic disease characterized by a reduction in bone mass and a microarchitectonic alteration of the skeleton, with a consequent increase in skeleton fragility and susceptibility to fractures”, as defined by the last Consensus Development Conference1. With this definition, the alteration in skeletal structure, which is not yet easy to evaluate, becomes an important factor determining the risk of fracture of the osteoporotic patient, in addition to the bone mass, which to certain limit can be easily evaluated. This is an aspect that may create some problems at the time of taking a decision on how to proceed with a subject with decreased bone mass. Currently, the measurement of the quantity of bone present constitutes the basis to support any therapeutical decision2. The quantification of bone mass may be performed with DEXA, TAC or ultrasound, although this last method has not been yet adequately standardized.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Consensus Development Conference. Prophylaxis and treatment of osteoporosis. Am J Med, 1993;94:646–650.

    Article  Google Scholar 

  2. Barbagallo M, Passeri M. Diagnostica strumentale della osteoporosi. Terapia Moderna, 1989;3:181–184.

    Google Scholar 

  3. Parfitt AM. Quantum concept of bone remodeling and turnover: Implications for the pathogenesis of osteoporosis. Calc Tissue Int 1979;28:1–5.

    Article  CAS  Google Scholar 

  4. Manolagas SC, Jilka RL. Mechanisms of disease: bone marrow, cytokines and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. N Engl J Med 1995, 332:305–311.

    CAS  Google Scholar 

  5. Riis BJ. Biochemical markers of bone turnover in diagnosis and assessment of therapy. Am J Med 1991;91(suppl.5B):64S–68S.

    Article  PubMed  CAS  Google Scholar 

  6. Garnero P, Häuser E, Chapui MC, et al. Can markers (MK) of bone turnover predict hip fractures (FX) in elderly women? J.Bone Min Res 1995; 10(suppI 1):S140.

    Google Scholar 

  7. Barbagallo M. Valore degli indici di turnover osseo nell’osteoporosi. Giorn. Gerontol 1989;37:255–264.

    Google Scholar 

  8. Uebellart D, Gineyts E, Chapui MC, Delmas PD. Urinary excretion of pyridinium crosslinks: a new marker of bone résorption in metabolic bone disease. Bone Miner 1990;8:87–96.

    Article  Google Scholar 

  9. Schiele F, Henny J, Hitz S, Peticlerc C, Gueguen R, Siest G. Total, bone and liver alkaline Phosphatase in plasma: Biological variation and reference limits. Clin.Chem 1983;23:634–641.

    Google Scholar 

  10. Eastell R, Delmas PD, Hodgson SF, Eriksen EF, Mann KG, Riggs BL. Bone formation rate in older normal women: concurrent assessment with bone histomorphometry, calcium kinetics, and biological markers. J Clin Endocrinol Metab 1988;67:741–748.

    Article  PubMed  CAS  Google Scholar 

  11. Garnero P, Delmas PD. Assessment of the serum levels of bone alkaline Phosphatase with a new immunoradiometric assay in patients with metabolic bone disease. J Clin Endocrinol Metab 1993;77:1046–1053.

    Article  PubMed  CAS  Google Scholar 

  12. Epstein S, Poser J, McClintock R, Johnston CC, Brycs G, Hui S. Differences in serum bone Gla protein with age and sex. Lancet 1984;ii: 118–120.

    Google Scholar 

  13. Delmas PD, Stenner D, Wahner HW, Mann KG, Riggs BL. Increase in serum bone gamma-carboxyglutamic acid protein with aging in women. J Clin Invest 1983;71:1316–1321.

    Article  PubMed  CAS  Google Scholar 

  14. Pedrazzoni M, Ciotti G, Davoli L, Barbagallo M, et al. Variazioni dell’osteocalcina sierica con l’età in soggetti normali. Giorn Gerontol 1988;36:419–424.

    Google Scholar 

  15. Kamel S, Brazier M, Neri V, et al. Multiple molecular forms of pyridinolines cross-links excreted in human urine evaluated by Chromatographic and immunoassay methods. J Bone Min Res 1995;10:1385–1392.

    Article  CAS  Google Scholar 

  16. Gallagher JC, Riggs BL, Jerpbak CM. The effect of age on serum immunoreactive parathyroid hormone in normal and osteoporotic women. J Lab Clin Med 1980;95:372–385.

    Google Scholar 

  17. Marcus R, Madvig P, Young G. Age-related changes in parathyroid hormone and parathyroid hormone action in normal humans. J Clin Endocrinol Metab 1984;58:223–230.

    Article  PubMed  CAS  Google Scholar 

  18. Johansen J, Riss BJ, Delmas PD, et al. Plasma BGP: an indicator of spontaneous bone loss and effect of estrogen treatment in postmenopausal women. Eur J Clin Invest 1988;18:191–195.

    Article  PubMed  CAS  Google Scholar 

  19. Uebellhart D, Schlemmer A, Johansen Gineyts E., Christiansen C, Delmas PD. Effect of menopause and hormone replacement therapy on the urinary excretion of pyridinium cross-links. J Clin Endocrinol Metab 1991;72:367–373.

    Article  Google Scholar 

  20. Szulc P, Chapui MC, Meunier PJ, Delmas PD. Serum undercarboxylated osteocalcin is a marker of the risk of hip fracture in elderly women. J Clin Invest 1993;91:1769–1774.

    Article  PubMed  CAS  Google Scholar 

  21. Alekson K, Vergnaud P., Gineyts E, Delmas PD. Increased bone resorption and decreased bone formation in elderly women with hip fracture. Bone Miner 1992; 17(S1): 184.

    Google Scholar 

  22. Delmas PD. Biochemical markers of bone turnover I: Theoretical consideration and clinical use in osteoporosis. Am J Med 1993;95(suppl.5A):11S–16S.

    Article  PubMed  CAS  Google Scholar 

  23. NIH Consensus Development Panel on Optimal Calcium Intake. Optimal Calcium Intake. JAMA 1994;272:1942–1948.

    Article  Google Scholar 

  24. Nordin BEC. Calcium balance and calcium requirements in spinal osteoporosis. Am J Clin Nutr 1962;10:384–390.

    PubMed  CAS  Google Scholar 

  25. Riggs BL, Wahner HW, Melton LJ III, Richelson LS, Judd HL, O’Fallon M. Dietary calcium intake and rates of bone loss in women. J Clin Invest 1987;80:979–982.

    Article  PubMed  CAS  Google Scholar 

  26. Heaney RP, Recker RR, Stegman MR, Moy AJ. Calcium absorption in women: relationship to calcium intake, estrogen status, and age. J Bone Miner Res 1989;4:469–475.

    Article  PubMed  CAS  Google Scholar 

  27. Baker MR, Peacok M, Nordin BEC. The decline in vitamin D status with age. Age Ageing 1980;9:249–252.

    Article  PubMed  CAS  Google Scholar 

  28. Orwoll ES, Meier DE. Alterations in calcium, vitamin D and parathyroid hormone physiology in normal men with aging; relationship to the developent of senile osteopenia. J Clin Endocrinol Metab 1986;63:1262–1269.

    Article  PubMed  CAS  Google Scholar 

  29. Heaney RP. Effect of calcium on skeletal development, bone loss and risk of fractures. Am J Med 1991;91(suppl.5B):23S–27S.

    Article  PubMed  CAS  Google Scholar 

  30. Cummings RG. Calcium intake and bone mass: a quantitative review of the evidence. Calc Tissue Int 1990;47:194–201.

    Article  Google Scholar 

  31. Kelly PJ, Pocock NA, Sambrook PN, Eismann JA. Dietary calcium, sex hormones, and bone mineral density in men. Br Med J 1990;300:1361–1364.

    Article  CAS  Google Scholar 

  32. Hui SL, Siemends CW, Johnston CC. Age and bone mass as predictors of fracture in a prospective study. J Clin Invest 1988;81:1804–1809.

    Article  PubMed  CAS  Google Scholar 

  33. Lindsay R, Hart DM, Forrest C, Baird C. Prevention of spinal osteoporosis in oophorectomized women. Lancet 1980;ii:1151–1154.

    Article  Google Scholar 

  34. Riggs BL, Melton LJ. The prevention and treatment of osteoporosis. N Engl J Med 1992;327:620–627.

    Article  PubMed  CAS  Google Scholar 

  35. Barbagallo M, Carbognani A, Palummeri E, et al. The comparative effect of ovarian sex steroids administration on bone mineral status in oophorectomized rats. Bone 1989; 10:113–116.

    Article  PubMed  CAS  Google Scholar 

  36. Girasole G, Jilka RL, Passeri G, et al. 17-beta estradiol inhibits interleukin-6 production by bone marrow-derived stromal cells and osteoblasts in vitro: a potential mechanism for the antiosteoporotic effect of estrogen. J Clin Invest 1992;89:883–891.

    Article  PubMed  CAS  Google Scholar 

  37. Jilka RL, Hangoc G, Girasole G, et al. Increased osteoclast development after estrogen loss: mediation by interleukin 6. Science 1992;257:88–91.

    Article  PubMed  CAS  Google Scholar 

  38. Passeri G, Girasole G, Jilka RL, Manolagas SC. Increased interleukin-6 production by murine bone marrow and bone cells after estrogen withdrawal. Endocrinology 1993;133:822–828.

    Article  PubMed  CAS  Google Scholar 

  39. Ettinger B, Genant HG, Cann CE. Long term estrogen therapy prevents bone loss and fracture. Ann Int Med 1985;102:319–324.

    Article  PubMed  CAS  Google Scholar 

  40. Kiel DP, Felson HT, Anderson JJ, et al. Hip fracture and the use of estrogens in postmenopausal women: the Framingham Study. N Engl J Med 1987;317:1169–1174.

    Article  PubMed  CAS  Google Scholar 

  41. Fleisch H. Bisphosphonates: pharmacology and use in the treatment of tumor-induced hypercalcemia and metastatic bone disease. Drugs 1991;42:919–944.

    Article  PubMed  CAS  Google Scholar 

  42. Shinoda H, Adamek G, Felik R, Fleisch H, Schenk R, Hagan P. Structure-activity relationship of various bisphosphonates. Calcif Tissue Int 1983;35:87–99.

    Article  PubMed  CAS  Google Scholar 

  43. Storm T, Thamsborg G, Steiniche T, et al. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 1990;322:1256–1271.

    Article  Google Scholar 

  44. Watts NB, Harris ST, Genant HG, et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 1990;323:73–79.

    Article  PubMed  CAS  Google Scholar 

  45. Schenk R, Eggli P, Fleisch H, Rosini S. Quantitative morphometric evaluation of the inhibitory activity of new aminobisphoshonates on bone resorption in the rat. Calc Tissue Int 1986;38:342–349.

    Article  CAS  Google Scholar 

  46. Passeri M, Baroni MC, Pedrazzoni M, Pioli G, Barbagallo M, Costi D, Biondi M, Girasole G, Arlunno B. Palummeri E. Intermittent treatment with intravenous 4-amino-l-hydroxybytilidene-l—1-bisphosphonate (AHBUBP) in the therapy of postmenopausal osteoporosis. Bone Miner 1991;15:237–238.

    Article  PubMed  CAS  Google Scholar 

  47. Chestnut CH, McClung MR, Ensrud KE, et al. Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling. Am J Med 1995;99:144–152.

    Article  Google Scholar 

  48. Adami S, Passeri M, Ortolani S, et al. Effects of oral alendronate and intranasal calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis. Bone 1995; 17: 383–390.

    Article  PubMed  CAS  Google Scholar 

  49. Liberman UA, Weiss SR, Broil J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal women. N Engl J Med 1995;333:1437–1443.

    Article  PubMed  CAS  Google Scholar 

  50. Overgaard K, Riis BJ, Christiansen C, et al. Effect of calcitonin given intranasally on early postmenopausal bone loss. Br Med J 1989;299:477–479.

    Article  CAS  Google Scholar 

  51. Avioli LV. Heterogeneity of osteoporotic syndromes and the response to calcitonin therapy. Calcif Tissue Int 1991;49(suppl. 2): S16–S19.

    Article  PubMed  Google Scholar 

  52. Passeri M, Palummeri E, Barbagallo M, et al. La sequenza calcitriolo-calcitonina nella terapia della osteoporosi. Minerva Endocrinol 1989;14:57–62.

    PubMed  CAS  Google Scholar 

  53. Burckardt P, Burnard B. The effect of treatment with calcitonin on vertebral fracture rates in established osteoporosis. Osteoporos Int 1993;3:24–30.

    Article  Google Scholar 

  54. Overgaard K, Hansen MA, Jensen SB, Christiansen C. Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study. Br Med J 1992;305:556–561.

    Article  CAS  Google Scholar 

  55. Chapui MC, Arlot ME, Dubouef F, et al. Vitamin D3 and calcium to prevent hip fracture in elderly women. N Engl J Med 1992;327:1637–1642.

    Article  Google Scholar 

  56. Reid IR, Ames RW, Evans MC, Gamble GD, Sharpe SJ. Effect of calcium supplementation on bone loss in postmenopausal women. N Engl J Med 1993;328:460–464.

    Article  PubMed  CAS  Google Scholar 

  57. Bonucci E, Ballanti P, Martelli A, et al. Ipriflavone inhibits osteoclastic differentiation in parathyroid transplanted parietal bone of rats. Calcif Tissue Int 1992;50:314–319.

    Article  PubMed  CAS  Google Scholar 

  58. Riggs BL, Hodgson SF, O’Fallon WM, et al. Fluoride treatment in osteoporotic women: effect on fracture rate in a 4-year controlled clinical trial. N Engl J Med 1990;322:802–809.

    Article  PubMed  CAS  Google Scholar 

  59. Hedlund LR, Gallagher JC. Increased incidences of fractures in osteoporotic patients treated with sodium fluoride. J Bone Min Res 1989;4:223–225.

    Article  CAS  Google Scholar 

  60. Riggs BL. Treatment of osteoporosis with sodium fluoride or parathyroid hormone. Am J Med 1991;91 (suppl 5B):37S–41S.

    Article  PubMed  CAS  Google Scholar 

  61. Pak CYC, Khashayar S, Adams-Huet B, Piziak V, Peterson RD, Poindexter JR. Slow-release sodium fluoride in the management of postmenopausal osteoporosis. Ann Int Med 1995;123:401–408.

    Article  PubMed  CAS  Google Scholar 

  62. Johansen JS, Hassager C, Podephant J. Treatment of postmenopausal osteoporosis. Is the anabolic steroid nandrolone decanoate a candidate? Bone Miner 1989;6:77–86.

    Article  PubMed  CAS  Google Scholar 

  63. Need AG, Chatterton BE, Walker CJ, Steiner TA, Horowitz M, Nordin BEC. Comparison of calcium, calcitriol, ovarian hormones and nandrolone in the treatment of osteoporosis. Maturitas 1986;8:275–280.

    Article  PubMed  CAS  Google Scholar 

  64. Tilyard MW, Spears GFS, Thompson J, Dovey S. Treatment of postmenopausal osteoporosis with calcitriol or calcium. N Engl J Med 1992;326:357–361.

    Article  PubMed  CAS  Google Scholar 

  65. Chapui MC, Arlot ME, Delmas PD, Meunier PJ. Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women. Br Med J 1994;308:1081–1082.

    Article  Google Scholar 

  66. Neer R, Slovik D, Daly M, Lo C, Potts J, Nussbaum S. Treatment of postmenopausal osteoporosis with daily parathyroid hormone plus calcitriol. In “Osteoporosis 1990”, Christiansen C, Overgaard K eds. Osteopress Aps, Copenhagen, 1990:pp. 1314-1317.

    Google Scholar 

  67. Mundy GR. Calcium Homeostasis: Hypercalcemia and hypocalcemia, 2nd ed. Martin Dunitz, London, 1990.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Geriatrics, Istituto di Medicina Interna e Geriatria, University of Palermo, Italy

    Mario Barbagallo, Ligia J. Dominguez & Giuseppe Barbagallo-Sangiorgi

  2. Istituto di Clinica Medica Generale e Terapia Medica, University of Parma, Italy

    Mario Passeri

Authors
  1. Mario Barbagallo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ligia J. Dominguez
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Giuseppe Barbagallo-Sangiorgi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mario Passeri
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. University of Palermo, Palermo, Italy

    Mario Barbagallo  & Giuseppe Licata  & 

  2. School of Medicine, Wayne State University, Detroit, Michigan, USA

    James R. Sowers

Rights and permissions

Reprints and permissions

Copyright information

© 1998 Springer Science+Business Media New York

About this chapter

Cite this chapter

Barbagallo, M., Dominguez, L.J., Barbagallo-Sangiorgi, G., Passeri, M. (1998). New Trends in the Treatment of Osteoporosis. In: Barbagallo, M., Licata, G., Sowers, J.R. (eds) Recent Advances in Geriatrics. Springer, Boston, MA. https://doi.org/10.1007/978-1-4899-1483-5_29

Download citation

  • DOI: https://doi.org/10.1007/978-1-4899-1483-5_29

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4899-1485-9

  • Online ISBN: 978-1-4899-1483-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation